Dynavax (DVAX -43%) gets creamed today, dropping steadily from the open and hitting a new...


Dynavax (DVAX -43%) gets creamed today, dropping steadily from the open and hitting a new 52-week low after the biopharm company reported that the FDA wants it to collect more saftety information from patients on Heplisav, its investigational adult hepatitis B vaccine.
From other sites
Comments (1)
  • fortuneteller1
    , contributor
    Comment (1) | Send Message
     
    I guess once Dynavax will go bankrupt, GSK will buy them out and get the FDA approval not granted thanks to the GSK-man chairing the FDA advisory board... Logic no? The big fish eats the small fish, and the regulators look somewhere else.
    11 Jun 2013, 02:30 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs